CA-CREATIVE-ARTISTS
17.4.2017 20:06:17 CEST | Business Wire | Press release
Creative Artists Agency (CAA), the world’s leading entertainment and sports agency, has partnered with CMC Capital Partners (CMC), China’s leading investment fund in media and entertainment, Internet and mobile, and lifestyle. The robust partnership includes the formation of CAA China, a world-class media and entertainment platform, and a minority strategic investment by CMC in CAA. Creating alignment throughout the agency, CMC Chairman Li Ruigang will join CAA’s Board of Directors.
Majority-owned by CAA, CAA China combines the expertise and vast resources of CAA with the broad reach and network of CMC in Greater China. CMC’s tremendous market experience in entertainment and sports combined with CAA’s representation of top Chinese talent, in addition to its leadership in film finance, will create a wide spectrum of new business and client opportunities in the swiftly growing Chinese market, ranging from talent representation, endorsements, and sports, to digital media, music, and original content production.
With more than two dozen employees in Beijing, CAA opened its China office in 2005 and has successfully built out its multiplatform approach to the market. The company has been at the center of every major Chinese co-production for the past 10 years and has packaged, sold, or raised financing for more than 75 Chinese-language film projects. CAA's Global Film Finance & Sales Group has directed more than $400 million in Chinese capital into English-language content. In addition, under the leadership of Jonah Greenberg, who runs the agency’s China efforts in motion pictures, CAA represents many of the most accomplished actors, directors, writers, and producers from Mainland China, Taiwan and Hong Kong, including Zhang Yimou, Lin Chi-ling, and Donnie Yen, among others.
“For more than a decade, we have served as a vital bridge to and within the Chinese market, utilizing our deep experience and network to support the work of the region’s best artists and to develop opportunities within the market for international talent,” said CAA President Richard Lovett. “CAA China will supercharge our efforts, from motion pictures, television, endorsements, and brand consulting to sports, live events, digital media, and beyond. CMC, under the leadership of Li Ruigang, has a remarkable record of success in the region, and we are confident that our partnership will yield tremendous results for our clients and future business partners in China.”
“We believe China and the US are the two biggest entertainment markets and play pivotal roles on the global landscape. The partnership not only creates commercial and industry value, but also serves as an innovative force in the evolution of the Chinese media industry,” said CMC Chairman Li Ruigang. “CAA is a prominent institution in the US entertainment and sports sector, which has built its success on systematically and consistently enabling the success of their clients throughout the years. We are immensely excited about the potential possibilities of an enhanced China angle by CMC coupled with the experience and resources of CAA. CMC has been in a highly productive cooperation with CAA under the leadership of Richard Lovett, and we look forward to greater accomplishments in the future.”
Founded by Li in 2010, CMC is a leading investor in media and entertainment, Internet and mobile, and lifestyle sectors in China. With a deep understanding of the China market, an extensive network of industry resources and prominent operational capabilities, CMC has invested and operated in Greater China, North America, Europe and Asian markets, and has created and supported the growth of many champions and emerging leaders in film, television, animation, kids content, sports, music, fashion, games, location-based entertainment, cinema, digital media, social platform, and entertainment technology. CMC’s previous and current investment and operational portfolio includes IMAX China; Star China, China’s top variety production company; Flagship, a joint venture studio with Warner Bros.; and City Football Group, a football club management company that owns Manchester City Football Club and New York City Football Club. Prior to founding CMC, Li was the Chairman and CEO of Shanghai Media Group (SMG) for more than ten years and successfully transformed SMG from a provincial broadcaster into a leading media conglomerate in China.
“CAA China demonstrates the vision and innovation that has driven CAA’s growth and fueled its ability to stay on the leading edge of industry trends,” said Jim Coulter, co-founder of private equity firm TPG, CAA’s majority shareholder. “CAA has had a significant impact on the Chinese entertainment marketplace by enabling its clients’ success over the past 12 years. We are thrilled with the company’s progress and the value-creation CAA has realized for its shareholders since our investment. With CMC as a meaningfully invested partner, and continuing growth in the Chinese market, the potential for CAA China is limitless.”
Greenberg will continue to lead CAA’s China efforts in motion pictures, working with the existing team in the Beijing office. Roeg Sutherland, Co-Head of CAA’s Global Film Finance and Sales Group, will continue to lead the agency’s film finance business in the market. CAA China will progressively add additional senior management to help expand the business into new entertainment and sports areas.
About Creative Artists Agency
Leading entertainment and sports agency Creative Artists Agency (CAA) represents many of the most successful professionals working in film, television, music, theatre, video games, sports, and digital content, and provides a range of strategic marketing and consulting services to corporate clients. CAA is also a leader in sports, representing more than 1,000 of the world’s top athletes in football, baseball, basketball, hockey, soccer, tennis, Olympics and action sports, and golf, and works in the areas of broadcast rights, corporate marketing initiatives, licensing, and sports properties for sales and sponsorship opportunities.
About CMC
CMC, founded and chaired by Li Ruigang, is China's leading investment and operating platform in media & entertainment, Internet & mobile, and lifestyle, and invests and operates in Greater China, north America, Europe and Asian markets. With a deep understanding of the China market, an extensive network of industry resources and prominent operational capabilities, CMC has created and supported the growth of many industry leaders in subsectors including film, television, animation, sports, music, fashion, games, advertising, marketing, financial media, location-based entertainment, cinema, online video platforms, OTT, smart TV and social media.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170417005739/en/
Contact:
Creative Artists Agency
424.288.2000
Michael Mand, Mmand@caa.com
Beth
McClinton, Beth.McClinton@caa.com
Missy
Davy, Mdavy@caa.com
or
CMC
Jiaming
Wu, Jiaming.Wu@cmccap.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
